Search
Research
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasiaWe report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PApilloma TRIal against Cancer In young Adults.
Research
Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccinationWe investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
Research
Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assaysUnambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...
Research
Neonatal antigen-presenting cells are functionally more quiescent in children born under traditional compared with modern environmental conditionsOne explanation for the high burden of allergic and autoimmune diseases in industrialized countries is inappropriate immune development under modern...
Research
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 yearsIn women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18
Research
Neutrophil Extracellular Traps and Bacterial Biofilms in Middle Ear Effusion of Children with Recurrent Acute Otitis MediaBacteria persist within biofilms on the middle ear mucosa of children with recurrent and chronic otitis media however the mechanisms by which these...
Research
Pandemic clinical case definitions are non-specificDuring the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.
Research
Predictors of Disease Severity in Children Hospitalized for Pertussis during an EpidemicThis study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean childrenInvasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.